Although the medical relevance on the aforementioned cardiovascular hazard factor alterations by tirzepatide will likely be assessed inside the prepared cardiovascular outcome study SURPASS-CVOT ( "kind":"medical-demo","attrs": "text":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Examination indicated that